Strategic infection prevention after genetically modified hematopoietic stem cell therapies: Recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee Review

   

Authors:	John, T. D.; Maron, G.; Abraham, A.; Bertaina, A.; Bhoopalan, S. V.; Bidgoli, A.; Bonfim, C.; Coleman, Z.; DeZern, A.; Li, J.; Louis, C.; Oved, J.; Pavel-Dinu, M.; Purtill, D.; Ruggeri, A.; Russell, A.; Wynn, R.; Boelens, J. J.; Prockop, S.; Sharma, A.
Review Title:	Strategic infection prevention after genetically modified hematopoietic stem cell therapies: Recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee
Abstract:	There is lack of guidance for immune monitoring and infection prevention after administration of ex vivo genetically modified hematopoietic stem cell therapies (GMHSCT). We reviewed current infection prevention practices as reported by providers experienced with GMHSCTs across North America and Europe, and assessed potential immunologic compromise associated with the therapeutic process of GMHSCTs described to date. Based on these assessments, and with consensus from members of the International Society for Cell & Gene Therapy (ISCT) Stem Cell Engineering Committee, we propose risk-adapted recommendations for immune monitoring, infection surveillance and prophylaxis, and revaccination after receipt of GMHSCTs. Disease-specific and GMHSCT-specific considerations should guide decision making for each therapy. © 2024 International Society for Cell & Gene Therapy
Keywords:	busulfan; rituximab; cd3 antigen; cd8 antigen; monitoring; cytology; consensus; infection; combination chemotherapy; aciclovir; cyclophosphamide; immunoglobulin; melphalan; hematopoietic stem cell transplantation; stem cell; antiinfective agent; immunoglobulin g; prophylaxis; vaccination; gene therapy; hematopoietic stem cells; allogeneic hematopoietic stem cell transplantation; hematopoietic stem cell; immunity; cd4 antigen; immunological monitoring; infection prevention; biological therapy; immunosurveillance; ex vivo study; cotrimoxazole; penicillin derivative; fluconazole; foscarnet; therapy; voriconazole; immunoglobulin g antibody; piperacillin plus tazobactam; fanconi anemia; immunocompromised patient; immune reconstitution; etiology; penicillin v potassium; adverse event; hemoglobinopathy; sulfamethoxazole; conditioning; procedures; infections; clinician; revaccination; piperacillin; cell engineering; tazobactam; genetic therapy; humans; human; article; cell- and tissue-based therapy; letermovir; genetically modified hematopoietic stem cell therapies
Journal Title:	Cytotherapy
Volume:	26
Issue:	7
ISSN:	1465-3249
Publisher:	Elsevier Science Ltd.
Date Published:	2024-07-01
Start Page:	660
End Page:	671
Language:	English
DOI:	10.1016/j.jcyt.2024.02.005
PUBMED:	38483362
PROVIDER:	scopus
PMCID:	PMC11213676
DOI/URL:	https://www.scopus.com/inward/record.uri?eid=2-s2.0-85187565252&doi=10.1016%2fj.jcyt.2024.02.005&partnerID=40&md5=859ab5d0228ac35773348b64e1bd5abf
Notes:	Article -- Source: Scopus

https://synapse.mskcc.org/synapse/works/has_related_data_chk/217635